What is PathoQuest?
PathoQuest specializes in biosafety assays utilizing next-generation sequencing (NGS) for biologics quality testing, focusing on GMP biotesting for biopharmaceuticals. Their services encompass adventitious virus testing, cell line characterization, and genetic analysis, serving global and emerging biopharma companies. PathoQuest's NGS platform provides an ethical and efficient alternative to traditional testing methods, aiming to enhance the safety and compliance of innovative biotherapies.
How much funding has PathoQuest raised?
PathoQuest has raised a total of $13.8M across 2 funding rounds:
Unspecified
$5M
Other Financing Round
$8.8M
Unspecified (2013): $5M with participation from Idinvest Partners, Kurma Partners, and Aurinvest
Other Financing Round (2019): $8.8M led by Idinvest Partners, investiere, Charles River Labs, French Public Program Investissement D'Avenir, Norgine, and Kurma Partners
Key Investors in PathoQuest
Idinvest Partners
Idinvest Partners is a mid-market private equity firm founded in 1997, specializing in financing and supporting entrepreneurs at various business development stages. They are headquartered in Paris, France.
Kurma Partners
Kurma Partners is a European venture capital firm focused on healthcare and biotechnology, investing from seed to growth stages. They aim to transform scientific discoveries into advanced medical solutions for severe diseases.
Norgine
Norgine is a leading European specialist pharmaceutical company, established in 1906 and headquartered in The Netherlands. They focus on bringing transformative medicines to patients.
What's next for PathoQuest?
The substantial enterprise-level funding indicates PathoQuest is in a scaling phase, likely focusing on expanding its technological capabilities and market reach. The recent strategic investment suggests a strong validation of its NGS-based approach to biopharmaceutical quality control. Future developments may include further integration of its services into the biopharma supply chain, enhanced regulatory compliance support, and potential expansion into new therapeutic areas requiring rigorous biosafety testing. This capital infusion is poised to solidify PathoQuest's position as a leader in advanced biosecurity solutions.
See full PathoQuest company page
